CXCL16



CXCL16

N1NN1E2EE2G3GG3S4SS4V5VV5T6TT6G7GG7S8SS8C9CC9Y10YY10C11CC11G12GG12K13KK13R14RR14I15II15S16SS16S17SS17D18DD18S19SS19P20PP20P21PP21S22SS22V23VV23Q24QQ24F25FF25M26MM26N27NN27R28RR28L29LL29R30RR30K31KK31H32HH32L33LL33R34RR34A35AA35Y36YY36H37HH37R38RR38C39CC39L40LL40Y41YY41Y42YY42T43TT43R44RR44F45FF45Q46QQ46L47LL47... and 178 more residue(s)...... and 178 more residue(s)

SMILES None
InChIKey None
Sequence NEGSVTGSCYCGKRISSDSPPSVQFMNRLRKHLRAYHRCLYYTRFQLLSWSVCGGNKDPWVQELMSCLDLKECGHAYSGIVAHQKHLLPTSPPISQASEGASSDIHTPAQMLLSTLQSTQRPTLPVGSLSSDKELTRPNETTIHTAGHSLAAGPEAGENQKQPEKNAGPTARTSATVPVLCLLAIIFILTAALSYVLCKRRRGQSPQSSPDLPVHYIPVAPDSNT

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections


No bioactivity data available.

CXCL16

N1NN1E2EE2G3GG3S4SS4V5VV5T6TT6G7GG7S8SS8C9CC9Y10YY10C11CC11G12GG12K13KK13R14RR14I15II15S16SS16S17SS17D18DD18S19SS19P20PP20P21PP21S22SS22V23VV23Q24QQ24F25FF25M26MM26N27NN27R28RR28L29LL29R30RR30K31KK31H32HH32L33LL33R34RR34A35AA35Y36YY36H37HH37R38RR38C39CC39L40LL40Y41YY41Y42YY42T43TT43R44RR44F45FF45Q46QQ46L47LL47... and 178 more residue(s)...... and 178 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections


Compound is not listed as a drug.